Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MR13A9 in hemodialysis patients with pruritus
NCT03802617Phase 2Completed
- Sponsor
- Kissei Pharmaceutical Co., Ltd.
- Start
- Feb 2019
- Primary completion
- Oct 2019
- Modality
- Peptides, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of difelikefalin in uremic pruritus (4 arms), sponsored by Kissei Pharmaceutical Co., Ltd. Primary endpoint: Numerical Rating Scale at 8 weeks. Started Feb 2019; status: completed.
02
Drugs
difelikefalin
03
Conditions
uremic pruritus
Beyond the preview
Go deeper on NCT03802617.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03802617.